ALLMedicine™ Retinal Detachment Center
Research & Reviews 2,354 results
https://doi.org/10.1038/s41433-022-02086-3 10.1159/000494687 10.1016/j.ophtha.2005.10.047 10.1136/bjophthalmol-2019-315432 10.1016/j.ajo.2011.01.021 10.1097/IAE.0000000000001708 10.1007/s00417-016-3371-5 10.2147/OPTH.S188309 10.1155/2020/3526316 10.1016/j.ophtha.2013.07.042 10.1016/j.ajo.2016.02.008 10.1097/IAE.0000000000001927 10.1038/eye.2014.312 10.1007/s00417-018-3995-8 10.1371/journal.pone.0232852 10.1016/j.ajo.2013.06.031 10.1007/s00417-012-2044-2 10.1016/j.ajo.2019.03.011 10.1167/iovs.61.4.33 10.1167/iovs.11-8557 10.1097/IAE.0000000000000390 10.1097/IAE.0000000000000163 10.1097/IAE.0000000000001069 10.1177/1120672120930590 10.1007/s10792-020-01674-0
Eye (London, England); Hsia Y, Lee CY et. al.
May 14th, 2022 - To study the development, evolution, outcomes, and prognostic factors of lamellar macular hole (LMH) in highly myopic (HM) patients. Fifty eyes from 47 HM patients with LMHs were retrospectively enrolled. Relevant pre- and post-LMH optical coheren...
https://doi.org/10.1186/s12886-022-02445-4 10.1155/2017/4310643 10.1016/j.ophtha.2016.03.032 10.1097/IAE.0000000000000050 10.1155/2018/8606494 10.1097/IAE.0000000000002464 10.1186/s12886-017-0459-6 10.1097/MD.0000000000010902 10.1001/archopht.123.8.1078 10.1097/IAE.0000000000000416 10.1097/IAE.0000000000002744 10.1136/bjophthalmol-2012-302140 10.1167/iovs.05-0981 10.1016/j.ajo.2013.09.011 10.1136/bjo.2004.043687 10.1111/j.1755-3768.2012.02455.x 10.1016/j.ophtha.2013.06.037 10.1097/IAE.0b013e3181e586f9 10.1016/j.ophtha.2006.05.039 10.1111/j.1755-3768.2009.01766.x 10.1097/IAE.0000000000000853 10.1097/00006982-199111040-00015 10.1155/2017/2565249 10.1016/j.ophtha.2004.12.046 10.1167/iovs.10-6872 10.1097/IJG.0000000000001785 10.1097/IAE.0000000000000094 10.1016/j.ophtha.2010.11.031 10.1007/s10792-019-01126-4 10.1186/s12886-021-02157-1
BMC Ophthalmology; Tang Y, Lin B et. al.
May 14th, 2022 - This study was investigated the surgical outcomes of primary rhegmatogenous retinal detachment (RRD) with inferior retinal breaks (IRBs) that were repaired by 25-gauge pars plana vitrectomy (PPV) with air tamponade. This retrospective review inclu...
https://clinicaltrials.gov/ct2/show/NCT04444492
May 11th, 2022 - Retinal vein occlusion (RVO) is the second most common retinal vascular disease leading to visual impairment. Main cause for visual impairment in CRVO (Central Retinal Vein Occlusion) is macular edema (ME) while neovascularization of the retina an...
https://doi.org/10.1136/bcr-2022-249746
BMJ Case Reports; Markan A, Mittal H et. al.
May 11th, 2022 - Pneumatic retinopexy as an approach to retinal detachment in a 30-weeks pregnant lady.|2022|Markan A,Mittal H,Singla P,Singh R,|diagnostic imaging,surgery,surgery,
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9070941
PloS One; Hänsli C, Lavan S et. al.
May 6th, 2022 - To find predictive markers for the visual potential in optical coherence tomography (OCT) one month after surgical repair of macula-involving rhegmatogenous retinal detachment (miRD) with and without internal limiting membrane (ILM) peeling. This ...
Drugs 2 results see all →
Clinicaltrials.gov 70 results
https://clinicaltrials.gov/ct2/show/NCT04444492
May 11th, 2022 - Retinal vein occlusion (RVO) is the second most common retinal vascular disease leading to visual impairment. Main cause for visual impairment in CRVO (Central Retinal Vein Occlusion) is macular edema (ME) while neovascularization of the retina an...
https://clinicaltrials.gov/ct2/show/NCT00110110
May 4th, 2022 - OBJECTIVES: Primary Compare the efficacy of neoadjuvant high-dose carboplatin and etoposide, vincristine, and cyclosporine (CSA) followed by ophthalmic focal therapy comprising cryotherapy and/or laser therapy to historical world data of chemother...
https://clinicaltrials.gov/ct2/show/NCT02834559
Apr 5th, 2022 - Proliferative vitreoretinopathy (PVR) is a common cause for postoperative failure after vitreoretinal surgery for primary RRD. There is no standard-therapy to prevent PVR. Several attempts using chemotherapeutic agents have been undertaken to prev...
https://clinicaltrials.gov/ct2/show/NCT03774992
Mar 4th, 2022 - Myopia is a common disease of the eye with increasing prevalence in the Western World as well as in South East Asia where 60-90% of the children are affected. A Danish study found that early debut of myopia is associated with a higher degree of my...
https://clinicaltrials.gov/ct2/show/NCT05195801
Jan 24th, 2022 - The optic nerve is part of the central nervous system and is surrounded by the dura, arachnoid, and pia mater; The sheath surrounding the optic nerve is in continuity with the dura mater of the brain and the subarachnoidal space filled with cerebr...
News 126 results
https://www.medscape.com/viewarticle/972431
Apr 20th, 2022 - Regular use of certain erectile dysfunction drugs — phosphodiesterase type 5 inhibitors (PDE5 inhibitors) — may be associated with an increased risk for several ocular adverse events, according to new research. In a cohort study of 213,033 men, th...
https://www.medscape.com/viewarticle/972271
Apr 18th, 2022 - (Reuters Health) - Men who regularly used Viagra and other popular erectile dysfunction prescription drugs were more likely to suffer visual impairment, including retinal detachment and blindness, a large cohort study finds. The adjusted risks for...
https://www.medscape.com/viewarticle/972064
Apr 13th, 2022 - People who use phosphodiesterase type 5 inhibitors (PDE5Is), a class of medications most often prescribed for erectile dysfunction, may run an increased risk of vision-threatening ocular conditions, researchers say. Patients in an insurance databa...
https://www.medpagetoday.com/ophthalmology/generalophthalmology/98101
Apr 7th, 2022 - Regular users of common medications for erectile dysfunction (ED) are at a higher risk for ocular adverse events, according to a large cohort study. Among over 200,000 men using phosphodiesterase type 5 inhibitors (PDE5Is), the adjusted incidence ...
https://www.medscape.com/viewarticle/961999
Nov 1st, 2021 - Updated November 3, 2021 // Editor's Note: This story has been updated with additional comments from Dr Christopher Starr and Eyenovia COO Michael Rowe. The US Food and Drug Administration for the first time has approved an eye drop to treat presb...